Inotuzumab Ozogamicin Active in Heavily Pretreated Indolent B-cell NHL

Share this content:
Investigational antibody-drug conjugate shows significant activity in patients with indolent B-cell non-Hodgkin lymphoma, but safety concerns remain.
Investigational antibody-drug conjugate shows significant activity in patients with indolent B-cell non-Hodgkin lymphoma, but safety concerns remain.

Inotuzumab ozogamicin demonstrated robust activity in heavily pretreated patients with indolent B-cell non-Hodgkin lymphoma, but treatment duration was limited by hematologic toxicities, a study published in the British Journal of Haematology has shown.1

Inotuzumab ozogamicin is an investigational antibody-drug conjugate composed of an anti-CD22 monoclonal antibody, which is expressed in about 90% of B-cell malignancies, linked to a cytotoxic agent.

Therefore, researchers sought to evaluate its efficacy and safety in patients with refractory indolent B-cell non-Hodgkin lymphoma.

For the phase 2 trial, researchers enrolled 81 patients refractory to rituximab alone, rituximab plus chemotherapy, or anti-CD20 radioimmunotherapy.

All participants received inotuzumab ozogamicin 1.8 mg/m2 intravenously for 4 to 8 28-day cycles. Those who achieved a complete response were eligible to receive 2 additional cycles.

RELATED: Inotuzumab Ozogamicin Granted Breakthrough Therapy Designation for Acute Leukemia

Results showed that 59% of patients received 3 or more cycles of inotuzumab ozogamicin and only 16% completed the treatment phase.

Researchers found that the overall response rate was 67%, with 31% achieving a complete response. Median progression-free survival was 12.7 months (95% CI, 8.9 - 26.9) and median overall survival had not yet been reached.

In regard to safety, hematologic adverse events were frequently reported, especially thrombocytopenia and neutropenia, which occurred in 74% and 56% of patients, respectively, and resulted in treatment discontinuation in 37% and 11%, respectively. A total of 58% of patients discontinued inotuzumab ozogamicin due to treatment-related toxicities.

Inotuzumab ozogamicin has also received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia. The decision was based on findings from the phase 3 INO-VATE ALL trial, which compared inotuzumab ozogamicin to standard of care chemotherapy.


  1. Goy A, Forero A, Wagner-Johnston N, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy [published online ahead of print April 22, 2016]. Br J Haematol. doi: 10.1111/bjh.14094.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs